Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

Stocks of COVID-19 vaccine makers take a dive following Washington Post report, while Moderna stresses multiple agencies have backed their safety Stocks of COVID vaccine makers dropped after the ...

Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...

Sept 3 (Reuters) - Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab on Wednesday defended their COVID-19 vaccines as having saved millions of lives worldwide, in separate responses to ...

A top adviser has resigned from the Food and Drug Administration's (FDA) vaccine advisory committee amid concerns about her ties to a pharmaceutical company conducting a trial for the highly ...

It is finally bouncing back after several challenging years.

FRANKFURT (Reuters) - Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty ...

GSK has secured an FDA expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus.